Ankylosing Spondylitis Market Report 2026

The ankylosing spondylitis market size has grown strongly in recent years. It will grow from $6.34 billion in 2025 to $6.85 billion in 2026 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to improved diagnostic awareness, wider availability of NSAIDs and DMARDs, increased specialist rheumatology services, expansion of hospital-based treatment access, growing use of imaging for disease monitoring.

The ankylosing spondylitis market size is expected to see strong growth in the next few years. It will grow to $9.42 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to rising adoption of biologics and biosimilars, increasing focus on personalized medicine, expansion of advanced biologic pipelines, growing demand for long-term disease management, increasing investments in autoimmune research. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of targeted DMARDs, growing focus on early disease diagnosis, expansion of personalized treatment approaches, enhanced integration of physical therapy programs.

The rising prevalence of autoimmune diseases is expected to drive the growth of the ankylosing spondylitis market in the coming years. Autoimmune diseases encompass a wide range of disorders characterized by an abnormal immune response, where the immune system mistakenly attacks and damages healthy cells, tissues, and organs. Conditions such as ankylosing spondylitis occur when the immune system targets the body’s own tissues, resulting in inflammation and tissue damage. Both genetic predisposition and environmental factors play a role in the development of ankylosing spondylitis, a type of autoimmune arthritis that primarily affects the spine and pelvis. For example, in September 2023, the Impact of IBD Report 2023, published by the IBD Clinical and Research Centre, a Canada-based organization dedicated to improving the lives of patients with Crohn’s disease and ulcerative colitis, reported a prevalence of 825 per 100,000 in 2023. This means over 320,000 people in Canada are living with inflammatory bowel disease (IBD), and with an expected annual prevalence increase of 2.44%, approximately 1.1% of the population, or 470,000 Canadians, are projected to have IBD by 2035. Consequently, the growing incidence of autoimmune diseases is anticipated to propel the future growth of the ankylosing spondylitis market.

Major companies operating in the ankylosing spondylitis market are concentrating on developing advanced biologic therapies, including biosimilars, to improve patient access, lower treatment costs, and offer familiar administration methods. Biosimilars are therapeutics that utilize the established active ingredients of reference biologics while maintaining comparable efficacy and safety profiles. For example, in August 2025, Amgen Biotechnology Singapore, a Singapore-based biotech company, obtained approval for its biosimilar adalimumab (Amgevita) in both a 40 mg/0.4 mL autoinjector and a 20 mg/0.2 mL prefilled syringe. This treatment is indicated for alleviating signs and symptoms in adult patients with active ankylosing spondylitis who have not responded adequately to conventional therapy. By offering familiar administration routes, leveraging a well-established active ingredient, and providing a more cost-effective option in the biologics sector, it aims to enhance patient outcomes.

In July 2023, Superior Biologics, Inc., a US-based specialty pharmacy and home infusion therapy service provider, and Coherus BioSciences, Inc., announced a national distribution agreement. This collaboration is designed to offer nationwide distribution of YUSIMRY, a biosimilar of Humira, providing patients with a high-quality, cost-effective treatment for conditions such as ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease, while enabling employers to reduce specialty drug expenses by over 85%. Coherus BioSciences, Inc. is a US-based biopharmaceutical company that offers a biosimilar product for ankylosing spondylitis (AS) called YUSIMRY (adalimumab-aqvh).

Major companies operating in the ankylosing spondylitis market are Pfizer Inc., Johnson & Johnson Pvt. Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Viatris Inc., Astellas Pharma Inc., AstraZeneca plc, UCB Inc., Cipla Inc., Zydus Lifesciences Limited, Celltrion Inc., Hetero Labs Ltd., Janssen Biotech Inc., Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the ankylosing spondylitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ankylosing spondylitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ankylosing spondylitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the ankylosing spondylitis market by increasing costs of imported biologic drugs, biosimilars, active pharmaceutical ingredients, and specialized manufacturing inputs used in advanced therapies. Hospitals and clinics in North America and Europe are most affected due to reliance on cross-border biologics supply chains, while Asia-Pacific faces pricing pressure on imported specialty drugs. These tariffs contribute to higher treatment costs and reimbursement challenges. However, they are also encouraging regional biologics manufacturing, local API production, and long-term investment in domestic pharmaceutical capabilities.

The ankylosing spondylitis market research report is one of a series of new reports that provides ankylosing spondylitis market statistics, including ankylosing spondylitis industry global market size, regional shares, competitors with a ankylosing spondylitis market share, detailed ankylosing spondylitis market segments, market trends and opportunities, and any further data you may need to thrive in the ankylosing spondylitis industry. This ankylosing spondylitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ankylosing spondylitis (AS) is a long-term inflammatory condition that mainly impacts the spine and sacroiliac joints, which connect the lower spine to the pelvis. It causes inflammation of the joints and entheses, affecting the joints and resulting in pain, stiffness, and a gradual reduction in spinal mobility.

The primary treatment for ankylosing spondylitis involves painkillers and non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biological therapies, steroids, physical therapies, and surgery. Painkillers and NSAIDs are medications that inhibit the production of specific chemicals in the body responsible for pain and swelling, and they are used in ankylosing spondylitis management to alleviate pain and reduce inflammation. Biologics, biosimilars, and small molecules are delivered through parenteral, oral, and other routes for use in both juveniles and adults by hospitals, clinics, research laboratories, and other end users.

The ankylosing spondylitis market consists of sales of nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitors, interleukin inhibitors, and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.